The UK’s leading pharmaceutical trade body, the Association of the British Pharmaceutical Industry (ABPI), has appointed Pfizer UK’s managing director Erik Nordkamp as president.
Mr Nordkamp said he would focus on “improving access to new medicines and vaccines,” as well as “ensuring that Britain holds on to its status as a world leader in global medicines discovery now and post-Brexit.”
He said: “The industry’s collaboration with government in producing the Life Science Industrial Strategy has set the right tone of partnership and agenda setting.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze